Jens Benn Sørensen
University of Copenhagen · 214 works · 5,588 citations · h-index 40
Top works
- Acute tumor lysis syndrome in solid tumors—a case report and review of the literature
- Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis.
- Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
- Prognostic factors in resected stages I and II adenocarcinoma of the lung
- Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease
- Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs.
- Prognostic impact of histologic demonstration of Chromogranin A and Neuron Specific Enolase in pulmonary adenocarcinoma
- Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
- Endobronchial metastases from extrapulmonary solid tumors
- 1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer
- Prognostic implications of histopathologic subtyping in patients with surgically treated stage I or II adenocarcinoma of the lung
- The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease
- Clinical impact of ki-67 labeling index in non-small cell lung cancer
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
- Metastatic pattern in adenocarcinoma of the lung
- Fluorouracil Induces Myocardial Ischemia With Increases of Plasma Brain Natriuretic Peptide and Lactic Acid but Without Dysfunction of Left Ventricle
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity
- Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
- Metastatic spinal cord compression secondary to lung cancer.